Navpriya Oberoi, MD
Gynecology · Fayetteville, NYNPI 1851538045
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Pfizer at 43.2% of the total. Reporting peaked in 2022 at $8,599 and has fallen 94.8% since, to $443 in 2025. Among gynecology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 253 payments — averaging $99.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$11K
- Intuitive Surgical$6K
- Coloplast$2K
- Lumenis BE Inc$2K
- AbbVie$1K
- Astellas Pharma US Inc$700
- plus $2K from 23 others
Across 42 payments — averaging $4166.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$175K
What the payments were for
- Consulting fees$2451%
- Speaking & faculty fees$13,72654%
- Travel & lodging$4,13316%
- Food & beverage$6,70127%
- Education$3812%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 21 | $10,869 |
| Intuitive Surgical | 30 | $6,121 |
| Coloplast | 28 | $2,287 |
| Lumenis BE Inc | 1 | $1,842 |
| AbbVie(2 entities) | 45 | $1,051 |
| Astellas Pharma US Inc | 24 | $700 |
| Therapeuticsmd, Inc. | 11 | $328 |
| Sumitomo Pharma America, Inc. | 15 | $258 |
| Exeltis, USA Inc. | 17 | $252 |
| Myovant Sciences Inc. | 12 | $191 |
| Mayne Pharma Commercial LLC | 10 | $188 |
| Boston Scientific | 4 | $127 |
| AstraZeneca | 1 | $125 |
| Caldera Medical, Inc | 4 | $125 |
| Agile Therapeutics, Inc. | 7 | $116 |
| Aspira Women's Health Inc | 1 | $84 |
| Millicent US Inc | 4 | $75 |
| Valencia Technologies Corporation | 2 | $61 |
| Boehringer Ingelheim | 1 | $60 |
| Axonics, Inc. | 2 | $59 |
| Hologic Sales And Service, LLC | 2 | $48 |
| Mylan Pharmaceuticals Inc. | 2 | $45 |
| Urovant Sciences Inc | 2 | $40 |
| Scynexis, Inc. | 2 | $36 |
| Medtronic | 1 | $27 |
| Exact Sciences | 1 | $23 |
| Merck | 1 | $22 |
| Avion Pharmaceuticals | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYFEMBREE$6,745
- Da Vinci Surgical System$5,199
- M22$1,842
- ALTIS$1,683
- DA VINCI SP$500
- ORIAHNN$245
- AIRSUPRA$125
- IMVEXXY$111
How this compares
$25,185 in reported general payments places this provider in the 95th percentile of 240 gynecology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 87 | $75,368 |
| GemtesaVibegron | 69 | $62,307 |
| PremarinEstrogens, Conjugated | 69 | $27,274 |
| Estradiol | 261 | $23,588 |
| Mirabegron ErMirabegron | 16 | $8,661 |
| VeozahFezolinetant | 13 | $6,674 |
| Clobetasol Propionate | 29 | $1,690 |
| Risedronate Sodium | 34 | $1,616 |
| Cephalexin | 81 | $1,501 |
| DottiEstradiol | 18 | $1,340 |
| Estradiol (Once Weekly)Estradiol | 11 | $1,288 |
| Estradiol (Twice Weekly)Estradiol | 13 | $1,149 |
| Raloxifene Hcl | 23 | $943 |
| Medroxyprogesterone Acetate | 11 | $449 |
| ValacyclovirValacyclovir Hcl | 21 | $437 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq, Veozah | $700 | $82,043100 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $258 | $62,30769 claims |
| PfizerPremarin | $10,869 | $27,27469 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 240 gynecology providers in New York.
Other gynecology in Fayetteville
- Arnold AdvinculaNew York$2.1M
- Stephen CohenSyracuse$204K
- Susan KhalilStaten Island$115K
- Diane SutterKenmore$95K
- Tamara KolevNew York$91K
- Shane SoppSyracuse$84K
- Charles Ascher-WalshNew York$43K
- Paula CastanoNew York$31K
- David KurssWilliamsville$25K
- Christopher EswarNew York$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.